Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Scienture LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action for the company. This action is being handled by 1 distinct examiner in 1 distinct art unit. The prosecution profile is currently narrow, with all activity centered on a specific examiner. This indicates that the company's current interactions with the patent office are limited to a specific technical matter. The 1 distinct art unit ensures that the examination follows a uniform set of technical standards.
The busiest examiner is AL-AWADI, DANAH J, who has 1 pending office action. This examiner is the only one currently reviewing pending work for the portfolio. For the practitioner, this means that the success of the current prosecution cycle depends on effectively addressing the concerns of AL-AWADI, DANAH J. The involvement of 1 distinct art unit indicates a stable technical environment for the pending application. Strategy should be focused on the specific examination style and preferences of AL-AWADI, DANAH J to ensure a favorable outcome.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AL-AWADI, DANAH J | 1 | 54.2% | +13.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996995 | LONG-ACTING BUPIVACAINE MICROSPHERE FORMULATIONS | AL-AWADI, DANAH J | 39d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996995 | LONG-ACTING BUPIVACAINE MICROSPHERE FORMULATIONS | AL-AWADI, DANAH J | 39d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996995 | LONG-ACTING BUPIVACAINE MICROSPHERE FORMULATIONS | AL-AWADI, DANAH J | 1615 | §103§112 | Non-Final OA | 39d | Pending | Oct 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial